|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although aberrant expression of Runt-related transcription factor 3 (RUNX3) contributes to tumor progression and metastasis in a number of carcinomas, the status of RUNX3 and its correlation with prognosis in oral squamous cell carcinomas (OSCC) are still controversial.
|
28765934 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RUNX3 (runt-related transcription factor-3) is a known tumor suppressor gene which exhibits potent antitumor activity in several carcinomas.
|
23457532 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylation frequencies of 12 of the 16 genes were higher in EBV-associated gastric carcinomas than in EBV-negative controls, and the frequency of methylation of 6 specific loci (MINT2, MINT31, p14, p16, p73, and RUNX3) was significantly higher in EBV-associated gastric carcinomas than in EBV-negative controls.
|
23073987 |
2013 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of WIF1 and RUNX3 genes promoters was observed in 35% and 25% of carcinomas, respectively.
|
21819494 |
2011 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
RUNX3 is a known tumor suppressor gene in several carcinomas.
|
19336521 |
2009 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Methylation-specific PCR (MS-PCR) analysis of the CpG islands of RUNX3 showed the promoter region to be hypermethylated in 18 of 21 analyzed carcinomas (86%), whereas only two of nine normal endometria (22%) were methylated (p<0.01).
|
18572225 |
2008 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
According to our results, promoter hyper-methylation of RUNX3 was detected in the serum of 44 patients comprising breast 9/19 (47%), non-small cell lung 11/20 (55%), gastric 4/4 (100%), pancreatic 2/2 (100%), colorectal 11/17 (65%) and liver 7/8 (88%) carcinomas.
|
17914577 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas.
|
16091737 |
2005 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of the RUNX3 promoter was found in 57 (71%) of 80 gastric carcinomas, and promoter hypermethylation of RUNX3 occurred more frequently in intestinal and diffuse-adherent type tumors than in diffuse-scattered type tumors (p = 0.046).
|
15051926 |
2004 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The methylation frequencies of CHFR, DAP-kinase, E-cadherin, hMLH1, p16, RASSF1A, and RUNX3 genes were 16.2%, 21.4%, 27.0%, 8.1%, 24.3%, 27.0%, and 56.8%, respectively, in primary biliary tract carcinomas.
|
15471559 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently, frequent inactivation of RUNX3 has been demonstrated in human gastric carcinomas.
|
14743205 |
2004 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The RUNX3 methylation was found in 8.1% of chronic gastritis (n=99), 28.1% of intestinal metaplasia (n=32), 27.3% of gastric adenomas (n=77) and 64% of gastric carcinomas (n=75), but not in chronic hepatitis B, normal prostate and colon mucosa, even though in cases of chronic hepatitis, the methylation frequency of its neoplastic tissues was very high.
|
14968123 |
2004 |